Effects of phenylbutazone on glucose tolerance and on secretion of insulin in healthy geldings.

This research examines how the medication phenylbutazone affects the glucose tolerance and insulin secretion in healthy male horses, finding that the medication significantly reduces fasting glucose levels without significant impacts on insulin levels or glucose tolerance.

Study Subject and Methodology

• The study involved a sample of six healthy geldings (neutered male horses).
• The horses were administered phenylbutazone with the dose of 4.4 mg/kg of the horse body weight. The medication was provided intravenously every 24 hours for a duration of 5 days.
• The study main aim was to examine the effect of phenylbutazone on glucose tolerance and insulin secretion.

Key Findings

• The use of phenylbutazone significantly lowered the fasting concentrations of glucose in the plasma of the healthy geldings under observation.
• However, despite this reduction, phenylbutazone treatment did not result in a significant change in the serum concentration of insulin.
• The researchers also found no significant effect of phenylbutazone usage on glucose tolerance or insulin secretion.
• Furthermore, the area under the insulin/glucose ratio versus time curve also remained unchanged, as confirmed by paired t-test analysis. The area under this curve is often utilized as a measure of the body’s insulin response to glucose intake over time.

Implications and Conclusions

• The study results suggest that while phenylbutazone can reduce fasting glucose levels in horses, it does not appear to significantly affect insulin secretion or glucose tolerance, therefore it might not adversely affect the overall metabolic health of horses.
• However, it does indicate that it could potentially be used to lower the fasting glucose levels in horses which can have applications in managing conditions related to glucose levels.
• Nevertheless, further research may be necessary to draw more robust conclusions about the effects of phenylbutazone on glucose tolerance and insulin secretion, as well as its safety and efficacy for use in managing metabolic conditions in horses.